A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy

New England Journal of Medicine

Volumn 341, Issue 5, 1999, Pages 305-311

  Freifeld, Alison ^a,e   Marchigiani, Donna ^a   Walsh, Thomas ^a   Chanock, Stephen ^a   Lewis, Linda ^a   Hiemenz, John ^c   Hiemenz, Sharon ^c   Hicks, Jeanne E ^b   Gill, Vee ^b   Steinberg, Seth M ^a   Pizzo, Philip A ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CELLULITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CLAVULANIC ACID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FEVER; FEVER OF UNKNOWN ORIGIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 0033615008     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199907293410501     Document Type: Article

References (23)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
3. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-65.
4. Rubin MM, Hathom JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988;6:167-84.
5. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8.
6. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
7. Malik I, Abbas Z, Karim M Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6. [Erratum, Lancet 1992;340:128.]
8. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
9. Rubenstein EB, Rolston KVI. Outpatient treatment of febrile neutropenic patients with cancer. Eur J Cancer 1995;31A:2-4.
10. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
11. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995-13:165-76.
12. Cancer Therapy Evaluation Program. Common toxicity criteria (CTC v2.0). Bethesda, Md.: National Cancer Institute, 1998. (See http:// ctep.info.nih.gov/CTC3/ctc.htm.) (Sec NAPS document no. 05527 for 34 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)
13. Camp A. Articular index for the assessment of rheumatoid arthritis. Orthopaedics 1971;4:39-45.
14. Ritchic DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. OJM 1968;37:393-406.
15. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;62:1037-40.
16. Malik IA, Khan WA, Aziz Z, Karim M. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 1994;19:522-7.
17. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of out-patient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
18. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979;51:177-87.
19. Schaad U, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologie and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991;10:723-9.
20. Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J 1997;16:118-22.
21. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991;2:485-7.
22. Lau RC, Doyle JJ, Freedman MH, King SM, Richardson SE. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pcdiatr Hematol Oncol 1994;11:417-21.
23. Vallejo C, Caballero MD, Garcia-Sanz R, et al. Sequential intravenousoral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematol Cell Ther 1997;39:223-7.